See What HealthDay Can Do For You
Contact Us

IL-18 Could Benefit Wet Age-Related Macular Degeneration

Prevents choroidal neovascularization; no impact on retinal pigment epithelial cell viability in mice

IL-18 Could Benefit Wet Age-Related Macular Degeneration

MONDAY, April 7, 2014 (HealthDay News) -- The inflammatory cytokine interleukin-18 (IL-18) prevents choroidal neovascularization but does not affect retinal pigment epithelial cell viability, and may be a viable therapeutic option for wet age-related macular degeneration, according to an experimental study published in the April 2 issue of Science Translational Medicine.

Sarah L. Doyle, Ph.D., from Trinity College Dublin, and colleagues examined the role of IL-18 in a mouse model of wet age-related macular degeneration.

The researchers found that IL-18 regulated choroidal neovascularization formation. Exogenous administration of mature recombinant IL-18 had no impact of the viability of retinal pigment epithelial cells. However, retinal pigment epithelial swelling and atrophy were caused by overexpression of pro-IL-18 or pro-IL-1β alone. Comparing mature recombinant IL-18 with current anti-vascular endothelial growth factor (VEGF)-based therapies showed that IL-18 treatment worked effectively alone and more effectively in combination with anti-VEGF therapies.

"Our findings represent a potential new therapeutic strategy for the treatment of this incurable disease," the authors write.

One author is employed by GlaxoSmithKline, which is developing IL-18 for the treatment of wet age-related macular degeneration and funded the study.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.